z-logo
open-access-imgOpen Access
FORMULATION AND EVALUATION OF LIQUISOLID COMPACTS OF LORNOXICAM
Author(s) -
Asma A. Mokashi,
Snehalata L. Gaikwad
Publication year - 2019
Publication title -
international journal of pharmacy and pharmaceutical sciences/international journal of pharmacy and pharmaceutical sciences
Language(s) - English
Resource type - Journals
eISSN - 2656-0097
pISSN - 0975-1491
DOI - 10.22159/ijpps.2019v11i6.28328
Subject(s) - lornoxicam , differential scanning calorimetry , dissolution , crystallinity , solubility , materials science , fourier transform infrared spectroscopy , scanning electron microscope , nuclear chemistry , chemistry , chemical engineering , composite material , pharmacology , organic chemistry , medicine , physics , analgesic , engineering , thermodynamics
Objective: Objective of the present investigation was to enhance the solubility and dissolution rate of poorly water-soluble drug lornoxicam using liquisolid technique with comparative determination of in vitro release profile of liquisolid compacts and conventional formulation of lornoxicam. Methods: Formulation was prepared by a liquisolid technique using different drug concentration in a liquid vehicle and different carrier/coating ratio. Prepared liquisolid compact was evaluated for Fourier transform infrared (FTIR) spectra analysis, differential scanning calorimetry (DSC), X-ray diffraction (P-XRD), scanning electron microscopy (SEM) and in vitro dissolution study. Results: The result showed that liquisolid compacts of lornoxicam displayed significantly higher drug release rate as compared to pure drug and conventional tablet prepared. The results of both DSC and X-ray crystallography indicated loss of crystallinity of the drug upon formulated into the liquisolid compact. Conclusion: Dissolution rate of the drug from liquisolid compacts was affected by changing the drug concentration and excipient ratio. The liquisolid technique appeared to be a promising approach for improving the dissolution of poorly soluble drug lornoxicam.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here